KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

被引：0
|
作者：
Schmid, Peter
Baccan, Carlos
Guo, Zifang
Tryfonidis, Kostas
Rugo, Hope S.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT1-18-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-18-06
引用
收藏
页数：3
相关论文
共 50 条
  • [1] KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
    Rugo, Hope S.
    Sohn, Joohyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Pablo Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Baccan, Carlos
    Tryfonidis, Konstantinos
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
    Schmid, Peter
    Sohn, Joo Hyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Hirshfield, Kim
    Tryfonidis, Konstantinos
    Rugo, Hope S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 233 - 234
  • [3] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Torregroza Otero, Marco
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmid, Peter
    LANCET, 2020, 396 (10265): : 1817 - 1828
  • [4] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhou, Xuan
    Karantza, Vassiliki
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2022, 82 (04)
  • [5] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    CANCER RESEARCH, 2017, 77
  • [6] Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmidi, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Tewari, K.
    Caceres, M. V.
    Alexandre, J.
    Monk, B.
    Fehm, T.
    Colombo, N.
    Hasegawa, K.
    Dubot, C.
    Li, J. J.
    Stein, K.
    Keefe, S.
    Shapira-Frommer, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162
  • [8] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [9] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [10] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345